BioPharmSignal logoBioPharmSignal

Biotech News

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Minerva Neuroscience (NERV)Minerva NeuroscienceConference / presentation

BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief

Related news

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

PRAXPraxis Precision Medicines2026-06-04 20:01 EST

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

HRMYHarmony Biosciences2026-05-27 12:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

ECORelectroCore2026-06-17 12:00 EST

electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference

NBIXNeurocrine Biosciences2026-05-26 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

View all latest news

Minerva Neuroscience

CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options. Roluperidone Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such...

Recent company news

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

NERVMinerva Neuroscience2026-05-05 12:00 EST

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-04-02 20:05 EST

Minerva Announces Leadership Transition

Stock data

Close
4.44 USD
Market cap
221.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States